153 related articles for article (PubMed ID: 34197012)
1. Rivaroxaban for treatment of livedoid vasculopathy: A systematic review.
Gao Y; Jin H
Dermatol Ther; 2021 Sep; 34(5):e15051. PubMed ID: 34197012
[TBL] [Abstract][Full Text] [Related]
2. Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial.
Weishaupt C; Strölin A; Kahle B; Kreuter A; Schneider SW; Gerss J; Eveslage M; Drabik A; Goerge T
Lancet Haematol; 2016 Feb; 3(2):e72-9. PubMed ID: 26853646
[TBL] [Abstract][Full Text] [Related]
3. Associations between coagulation factors and livedoid vasculopathy and the efficacy and safety of rivaroxaban in patients with livedoid vasculopathy: a retrospective study.
Zhao C; Yu M; Cheng X; Li S; Feng S
Clin Exp Dermatol; 2024 Jan; ():. PubMed ID: 38287670
[TBL] [Abstract][Full Text] [Related]
4. Comparative Efficacy of Rivaroxaban and Immunoglobulin Therapy in the Treatment of Livedoid Vasculopathy: A Systematic Review.
Ramphall S; Rijal S; Prakash V; Ekladios H; Mulayamkuzhiyil Saju J; Mandal N; Kham NI; Shahid R; Naik SS; Venugopal S
Cureus; 2022 Aug; 14(8):e28485. PubMed ID: 36051980
[TBL] [Abstract][Full Text] [Related]
5. Treatment application of rivaroxaban in Chinese patients with livedoid vasculopathy.
Chen W; Fan L; Wang Y; Deng X
J Pain Res; 2017; 10():621-624. PubMed ID: 28360530
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of intravenous immunoglobulin for treating refractory livedoid vasculopathy: a systematic review.
Gao Y; Jin H
Ther Adv Chronic Dis; 2022; 13():20406223221097331. PubMed ID: 35634570
[TBL] [Abstract][Full Text] [Related]
7. A Phase II Multicenter Trial With Rivaroxaban in the Treatment of Livedoid Vasculopathy Assessing Pain on a Visual Analog Scale.
Drabik A; Hillgruber C; Goerge T
JMIR Res Protoc; 2014 Dec; 3(4):e73. PubMed ID: 25500152
[TBL] [Abstract][Full Text] [Related]
8. The management of livedoid vasculopathy focused on direct oral anticoagulants (DOACs): four case reports successfully treated with rivaroxaban.
Franco Marques G; Criado PR; Alves Batista Morita TC; Cajas García MS
Int J Dermatol; 2018 Jun; 57(6):732-741. PubMed ID: 29663354
[TBL] [Abstract][Full Text] [Related]
9. Characteristics, risk factors and treatment reality in livedoid vasculopathy - a multicentre analysis.
Weishaupt C; Strölin A; Kahle B; Kreuter A; Schneider SW; Gerss J; Eveslage M; Drabik A; Goerge T
J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1784-1791. PubMed ID: 31009111
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of Xa inhibitors in patients with heart failure and coronary or peripheral artery disease: a systematic review and meta-analysis of randomized controlled trials.
Chen Y; Feng X; Qi C; Zhou L; Sun Y; Gu Z; Li X
Ann Palliat Med; 2021 Jul; 10(7):8082-8093. PubMed ID: 34353093
[TBL] [Abstract][Full Text] [Related]
11. Treatment for Livedoid Vasculopathy: A Systematic Review.
Micieli R; Alavi A
JAMA Dermatol; 2018 Feb; 154(2):193-202. PubMed ID: 29141075
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive review on pathogenesis, associations, clinical findings, and treatment of livedoid vasculopathy.
Seguí M; Llamas-Velasco M
Front Med (Lausanne); 2022; 9():993515. PubMed ID: 36569162
[TBL] [Abstract][Full Text] [Related]
13. Successful Treatment of Painful Cutaneous Vasculopathy With Rivaroxaban in a Patient With Systemic Lupus Erythematosus.
Leisenring NH; Rogers JL; Telloni S; Mansoori P; Al-Rohil RN; Marano AL
J Drugs Dermatol; 2020 May; 19(5):544-546. PubMed ID: 32484618
[TBL] [Abstract][Full Text] [Related]
14. Livedoid vasculopathy and its association with genetic variants: A systematic review.
Gao Y; Jin H
Int Wound J; 2021 Oct; 18(5):616-625. PubMed ID: 33686673
[TBL] [Abstract][Full Text] [Related]
15. Case series of recalcitrant livedoid vasculopathy treated with rivaroxaban.
Lee JM; Kim IH
Clin Exp Dermatol; 2016 Jul; 41(5):559-61. PubMed ID: 26993107
[No Abstract] [Full Text] [Related]
16. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
Ma G; Zhang R; Wu X; Wang D; Ying K
Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
[TBL] [Abstract][Full Text] [Related]
17. Pain Management Options in a Patient with Livedoid Vasculopathy and Peripheral Neuropathy.
Palanisamy N; Chinnappan J; Bachuwa G
Eur J Case Rep Intern Med; 2023; 10(1):003727. PubMed ID: 36819654
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of adding rivaroxaban to the anti-platelet regimen in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials.
Yuan J
BMC Pharmacol Toxicol; 2018 May; 19(1):19. PubMed ID: 29720261
[TBL] [Abstract][Full Text] [Related]
19. Chronic leg ulcerations associated with livedoid vasculopathy successfully treated with rivaroxaban.
Miguel D; Elsner P; Goetze S
Clin Exp Dermatol; 2020 Jan; 45(1):120-122. PubMed ID: 30767258
[No Abstract] [Full Text] [Related]
20. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
